This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Ophthalmology Podcasts

The Macular Minute Episode 2

with Rossella Anzidei

The Macular Minute Banner

Approval Procedure for Introducing EYLEA® (aflibercept) 8 mg into Clinical Practice

In this

3-minute
episode, we are joined by
Rossella Anzidei
, a Consultant Ophthalmologist at University Hospitals Leicester NHS Trust, to discuss
the approval procedure for introducing EYLEA 8 mg into clinical practice
.

 

This promotional podcast series has been organised and funded by Bayer and is for UK healthcare professionals only.

Prescribing information for EYLEA® (aflibercept) 8 mg

can be found here
.

Prescribing information for EYLEA® (aflibercept) 2 mg

can be found here
.

Rossella Anzidei

Ms Rossella Anzidei, FRCOphth, is a Consultant Ophthalmologist in University Hospitals of Leicester, specialised in Medical Retina conditions, including age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. Ms Anzidei has been Principal Investigator of randomized controlled trials and she is lecturer for the Medical School in Leicester. Ms Anzidei contributed to the expansion of the Macula Service and she received the 'Caring at its Best' Award from the University Hospitals of Leicester for the high-quality care and the improvement of NHS services.

 

Speaker Disclosures

Speaker and travel grants: AbbVie, Bayer and Novartis

References

  1. EYLEA® 40 mg/mL Summary of Product Characteristics.
  2. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2911, July 2025
The Macular Minute: Podcast Series
Your source for quick expert insights in medical retina
PP-EYL-GB-2538, January 2025
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025

PP-EYL-GB-2542 | December 2024